Rituximab and new regimens for indolent lymphoma: a brief update from 2012 ASCO Annual Meeting
Open Access
- 23 August 2012
- journal article
- review article
- Published by Springer Nature in Cancer Cell International
- Vol. 12 (1) , 38
Abstract
Indolent lymphoma (IL), the second most common lymphoma, remains incurable with chemotherapy alone. While R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) remains the standard frontline regimen for diffuse Large B –cell lymphoma, the optimal chemotherapy regimen for frontline therapy of advanced IL remains uncertain. FCR (fludarabine, cyclophosphamide, rituximab) has been shown to be better than fludarabine alone and fludarabine plus cyclophosphamide for IL. In FOLL05 trial, R-CHOP was compared with R-CVP (cyclophosphamide, vincristine, prednisone) and R-FM (fludarabine, mitoxantrone). The study showed that R-CHOP appears to have the best risk-benefit ratio for IL. The StiL NHL1 trial showed that BR (bendamustine, rituximab) has longer progression free survival and is better tolerated than R-CHOP. Long-term complications with secondary malignancies between the two regimens appear to be comparable. In this review, new combination regimens reported at 2012 ASCO annual meeting were evaluated for frontline and salvage therapy of indolent lymphoma.Keywords
This publication has 54 references indexed in Scilit:
- Phase 1b study of lenalidomide in combination with rituximab-CHOP (R2-CHOP) in patients with B-cell lymphomaLeukemia, 2012
- Clinical experience of bendamustine treatment for non-Hodgkin lymphoma and chronic lymphocytic leukemia in SpainLeukemia Research, 2012
- Is bendamustine an ideal partner for rituximab in the management of relapsed chronic lymphocytic leukemia? Results of a multicenter Phase II trialExpert Review of Hematology, 2012
- Successful administration of rituximab–bendamustine regimen in the relapse of Hodgkin lymphoma after autologous hemopoietic stem cell transplantationHematological Oncology, 2011
- High nuclear expression of STAT3 is associated with unfavorable prognosis in diffuse large B-cell lymphomaJournal of Hematology & Oncology, 2011
- Six of 12 Relapsed or Refractory Indolent Lymphoma Patients Treated 10 Years Ago with 131I-Tositumomab Remain in Complete RemissionJournal of Nuclear Medicine, 2011
- Targeted therapy in lymphomaJournal of Hematology & Oncology, 2010
- New targets for lymphoma treatmentAnnals of Oncology, 2008
- Rituximab in diffuse large B-cell lymphoma.2004
- Aggressive lymphoma: improving treatment outcome with rituximabAnti-Cancer Drugs, 2002